Literature DB >> 1679388

Testing the abuse liability of anxiolytic and hypnotic drugs in humans.

H de Wit1, R R Griffiths.   

Abstract

This paper represents a comprehensive review of laboratory studies investigating the abuse liability of anxiolytic and hypnotic drugs in humans. The subjective effects of these drugs, most of which are either barbiturates or benzodiazepines, have been measured using various self-report questionnaires and their reinforcing effects have been studied using self-administration and choice procedures. Studies using both subjective and reinforcing effects reveal orderly relations between the two main chemical classes of anxiolytic/hypnotics (e.g. barbiturates are associated with higher abuse liability than benzodiazepines), between different doses of the drugs (e.g. higher doses are usually associated with higher abuse liability) and among different compounds within a class. The subjective and reinforcing effects of barbiturates and benzodiazepines depend critically upon the subject populations that are tested and it is argued that individuals with histories of drug abuse provide a more sensitive indicator of abuse liability than healthy volunteers. Several principles of abuse liability testing are discussed, including the selection of an appropriate subject population, the use of blind drug administration procedures, the comparison of a test compound to an appropriate standard, the inclusion of a placebo and a wide range of doses of the test drug and the use of multiple measures of likelihood of abuse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679388     DOI: 10.1016/0376-8716(91)90054-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  40 in total

1.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

2.  Effects of nicotine on attention and inhibitory control in healthy nonsmokers.

Authors:  Nicholas D Wignall; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2011-06       Impact factor: 3.157

3.  Preference for diazepam, but not buspirone, in moderate drinkers.

Authors:  S M Evans; R R Griffiths; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  Subjective and behavioral effects of diazepam depend on its rate of onset.

Authors:  H de Wit; S Dudish; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 6.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

7.  Psychopharmacology of theobromine in healthy volunteers.

Authors:  Matthew J Baggott; Emma Childs; Amy B Hart; Eveline de Bruin; Abraham A Palmer; Joy E Wilkinson; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2013-02-19       Impact factor: 4.530

8.  Subjective Effects of Alcohol Predict Alcohol Choice in Social Drinkers.

Authors:  Jingfei Li; Conor H Murray; Jessica Weafer; Harriet de Wit
Journal:  Alcohol Clin Exp Res       Date:  2020-11-17       Impact factor: 3.455

Review 9.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

10.  Oral self-administration of triazolam, diazepam and ethanol in the baboon: drug reinforcement and benzodiazepine physical dependence.

Authors:  N A Ator; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.